Development of novel polypharmacology-based cancer immunotherapy strategies targeting the purinergic signalling pathway
Blocking the A2B Adenosine Receptor is a selective mechanism of therapeutic intervention, since this receptor is silent under physiological conditions. We will identify and optimize high affinity small-molecule antagonists for the A2BAR, and evolve these within a multitarget strategy that considers the related A2AAR, CD73 and the P2Y1 GPCR, involved in the purinergic signaling pathway that regulates immune responses in the cancer microenvironment. The goal is to deliver dual inhibitors of the purinergic signaling system.
Members (researchers): Hugo Gutiérrez de Terán Castañón
Research Groups: Computational Biochemistry of Membrane Receptors